Amarin Corporation(AMRN) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Amarin Reports Second Quarter 2025 Financial Results -- European Partnership with Recordati Established to Maximize VAZKEPA® in Europe; Global Corporate Restructuring Implemented with Anticipated $70 Million in Operating Expense Savings Over Next 12 Months -- -- Q2 2025 Financial Performance Reflects Incremental Progress for VASCEPA®/VAZKEPA® in Ex-U.S. Markets, and Continued Stability in U.S. Market -- -- Cash Position Sufficient to Fund Company's Future Growth Path -- DUBLIN, Ireland and BRID ...